UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Canada 98-0661854 (State or other jurisd ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2020 Earnings Conference Call May 21, 2020 4:30 PM ET Company Representatives Simon Pimstone - Chief Executive Officer Ian Mortimer - President, Chief Financial Officer Jodi Regts - VP, Corporate Affairs & IR Conference Call Participants Paul Matteis - Stifel Lachlan Hanbury-Brown - William Blair Eddie Hickman - Guggenheim Laura Chico - Wedbush Securities Maury Raycroft - Jefferies David Martin - Bloom Burton Operator Ladies and gentlemen, thank you for standing b ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Canada 98-0661854 (State or other juris ...

Xenon Pharmaceuticals, Inc. (NASDAQ:XENE) Q4 2019 Earnings Conference Call March 9, 2020 4:30 PM ET Company Participants Jodi Regts - VP, Corporate Affairs & IR Simon Pimstone - CEO & Director Ian Mortimer - President, CFO, COO & Company Secretary Conference Call Participants Paul Matteis - Stifel, Nicolaus & Company Lachlan Hanbury-Brown - William Blair & Company Yatin Suneja - Guggenheim Securities Maurice Raycroft - Jefferies Operator Ladies and gentlemen, thank you for standing by, and welcome to the Xe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36687 XENON PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) Canada 98-0661854 (State or other jurisdictio ...

将 XENON | SLIDE 1 Corporate Presentation December 2019 NASDAQ: XENE | www.xenon-pharma.com Forward Looking Statement/Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forwardlooking statements. All statements other than statements of historical fact co ...

Xenon Pharmaceuticals, Inc. (NASDAQ:XENE) Q3 2019 Earnings Conference Call November 5, 2019 4:30 PM ET Company Participants Jodi Regts - Vice President, Corporate Affairs and Investor Relations Simon Pimstone - Chief Executive Officer Ian Mortimer - President and Chief Financial Officer Conference Call Participants Alex Thompson - Stifel Swapnil Malekar - Jefferies Antonia Borovina - Bloom Burton Operator Ladies and gentlemen, thank you for standing by and welcome to the Q3 2019 Xenon Pharmaceuticals Inc Ea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. WASHINGTON, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR Canada 98-0661854 (State or other jurisdiction of incorporation or organization) 200-3650 ...

Xenon Pharmaceuticals, Inc. (NASDAQ:XENE) Q2 2019 Earnings Conference Call August 6, 2019 4:30 PM ET Company Participants Jodi Regts - IR Simon Pimstone - CEO & Director Ian Mortimer - President, CFO, COO & Company Secretary Conference Call Participants Alex Thompson - Stifel Swapnil Malekar - Jefferies Antonia Borovina - Bloom Burton & Co. Operator Good day, ladies and gentlemen, and welcome to the Second Quarter 2019 Xenon Pharmaceuticals Earnings Conference Call. [Operator Instructions]. As a reminder, t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Canada 98-0661854 (State or other jurisd ...